Type of spiritual experienceHallucination (16)
Nevirapine may cause severe or life-threatening liver toxicity, usually emerging in the first six weeks of treatment
A description of the experience
On Jan, 28, 2017 6,757 people reported to have side effects when taking Nevirapine. Among them, 11 people (0.16%) have Hallucination
On Jan, 31, 2017 6,757 people reported to have side effects when taking Nevirapine. Among them, 5 people (0.07%) have Hallucination, Auditory
Most common Nevirapine side effects
- Fever - (572 reports)
- Drug exposure during pregnancy - (433 reports)
- Hiv infection - (324 reports)
- Drug resistance - (303 reports)
- Drug ineffective - (299 reports)
- Rashes - (267 reports)
- Death - (262 reports)
- Anaemia - (257 reports)
- Nausea - (245 reports)
- Foetal exposure during pregnancy - (221 reports)
Nevirapine-associated early hepatotoxicity: incidence, risk factors, and associated mortality in a primary care ART programme in South Africa - Chu KM, Boulle AM, Ford N, Goemaere E, Asselman V, Van Cutsem G.; South African Medical Unit, Médecins Sans Frontières, Johannesburg, South Africa.
BACKGROUND: The majority of antiretroviral treatment programmes in sub-Saharan Africa are scaling up antiretroviral treatment using a fixed dose first-line antiretroviral regimen containing stavudine, lamivudine, and nevirapine. One of the primary concerns with the use of this regimen is nevirapine-associated hepatotoxicity.
METHODOLOGY/PRINCIPAL FINDINGS: Study participants were 1,809 HIV-infected, antiretroviral naïve adults initiating nevirapine-based antiretroviral therapy between November 2002 and December 2006. The primary outcome was early hepatotoxicity. Secondary outcomes were associations with hepatotoxicity and mortality at six months.
The cumulative proportion of early hepatotoxicity ranged from 1.0-2.0% giving an incidence-rate at 102 days of 3.6-7.6 per 100 person-years. Median time to hepatotoxicity was 32 (IQR 28-58) days.
…… No association was found between age, gender, baseline CD4 count, concurrent tuberculosis infection, prior participation in a prevention of mother-to-child-transmission program, or baseline weight and early hepatotoxicity. There was no association between early hepatotoxicity and mortality.